Posted by Michael Wonder on 25 May 2026
First medicine to treat rare uncontrolled growth of body tissues
22 May 2026 - Vijoice addresses an unmet medical need for patients with severe or life-threatening PIK3CA-related overgrowth spectrum disorders.
EMA has recommended granting a conditional marketing authorisation in the European Union for Vijoice to treat adults and children aged 2 years and older with severe or life-threatening PIK3CA-related overgrowth spectrum disorders.
